Article

Understanding the relevance of epigenetic reprogramming for resistance to HDAC inhibitors in cancer cells

2016-01-01

Abstract excerpt

Therapeutic responses to Histone deacetylase (HDAC) inhibitors (HDACi) in many cancers are well described but development of resistance to HDACi is a major stumbling block. Whether HDACis induce epigenetic reprogramming and how this contributes to relapse is not reported. A CTCL cell line HuT78, and a CLL cell line MEC1, were used to develop HDACi resistant clones (RHuT78 and RMEC1 respectively) that persistently...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d0088dcb-65f5-51c8-917e-fb70295f66e1
DOI: 10.17638/03004805

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 8 closest

Understanding the relevance of epigenetic reprogramming for resistance to HDAC inhibitors in cancer cellsDOI 10.17638/03004805Read

Histone Deacetylase Inhibitors: Emerging Mechanisms of ResistanceSemantic proximity Read

Romidepsin in peripheral and cutaneous T‐cell lymphoma: mechanistic implications from clinical and correlative dataSemantic proximity Read

Romidepsin for the treatment of cutaneous T-cell lymphomaSemantic proximity Read

Aberrant epigenetic silencing is triggered by a transient reduction in gene expression.Semantic proximity Read

Elevated HDAC activity and altered histone phospho-acetylation confer acquired radio-resistant phenotype to breast cancer cells.Semantic proximity Read

Can the state of cancer chemotherapy resistance be reverted by epigenetic therapy?Semantic proximity Read

Histone Deacetylase Inhibitor Romidepsin Inhibits<i>De Novo</i>HIV-1 InfectionsSemantic proximity Read

Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series reportSemantic proximity Read